PLx stockholders will receive newly issued shares of common stock of Dipexium in connection with the merger contemplated by the merger agreement. Dipexium will issue approximately 36 million new shares of its common stock …
Protalix BioTherapeutics, Inc. (NYSE: PLX) announced the entry into a definitive exchange ... approximately 23.8 million …
Investors in Protalix BioTherapeutics, Inc. PLX need to pay close attention to the stock based on moves in the options market lately. That is because the May 19 th 2017 $1.00 Call had some of the highest implied volatility of all equity …
dipexium will be renamed PLX Pharma Inc, and will operate under leadership of PLX management team * Dipexium Pharmaceuticals Inc - co to issue about 36 million new shares of common stock to PLX stockholders under exchange …
Under the terms of the agreement, unanimously approved by the boards of directors of both companies, IDT will acquire …
Among the companies with shares expected to actively trade in Tuesday’s session are PLX Technology Inc. (PLXT), P.F. Chang ... weighed on shares premarket; the stock fell 9.3% to $19.72. The drug developer’s stock has already tumbled …
PLx stockholders will receive newly issued shares of common stock of Dipexium in connection with the merger contemplated by the merger agreement. Dipexium will issue approximately 36 million new shares of its common stock …
Pluristem said it will start preparations to keep an emergency stock of PLX-R18 on hand for use in such events. Full approval of the drug will depend on the results of a Phase III clinical trial. Pluristem said on Monday it is in discussions …
PLX Technology, Inc. (NASDAQ: PLXT) announced it has signed a definitive agreement to acquire all of the outstanding shares of capital stock of Oxford Semiconductor, Inc., a privately held fabless provider of industry-leading silicon and …